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Objective: To verify possible associations between adenosine aminohydrolase (ADA)
and AMP-aminohydrolase (AMPDA) to E3 SUMO-protein ligase NSE2 (NSMCE2) in
patients with renal stones. And to isolate, purify and characterize ADA in patients with
renal stones and healthy group.
Methods: A total of 60 renal stones patients and 50 control were enrolled in a case–
control study. The blood urea, creatinine, uric acid, protein, albumin, ADA and AMPDA
were measured by colorimetric tests. The serum NSMCE2 was measured by ELISA.
Results: Serum ADA, AMPDA and speciﬁc activity of enzymes showed signiﬁcant
decrease (P < 0.05) in patients with renal stones compared to control group, mean levels
of sera NSMCE2 and uric acid had a signiﬁcant increase (P < 0.01 and P < 0.05,
respectively) in patients compared to control group.
Conclusions: The present study suggests that ADA, AMP deaminase and NSMCE2 can
be used as a indicator to monitor the DNA damage and inﬂammation disorders in the
patients with kidney stones.1. Introduction
Simple renal stones are common in adults, particularly in the old
population. They are crystal accumulations made in the kidneys
where recurrence of stone formation is common [1]. It is a very
common kidney disorder all over the world, an assessed lifetime
risk of 2%–5% in Asia and 8%–15% in Europe [2]. Thus around
40% of the stone formers do not produce another stone. Stone
formers with systemic diseases such as cystinuria, the mostimportant hyperoxaluria, and primary hyperparathyroidism have
more risks of recurrence [3]. The stones can form anywhere in
the urinary system, from kidneys to the bladder but in the
industrialized and afﬂuent societies, they are generally restricted
to the kidneys [2]. The information on chemical conﬁguration of
urinary lithiasis is a very important step in the treatment of this
disease [3].
Adenosine aminohydrolase (ADA) is a polymorphic enzyme
involved in purine metabolism and it is necessary in the purine
salvage pathway [4]. It catalyzes the irreversible deamination of
20-deoxyadenosine and adenosine to deoxyinosine and inosine.
It is found in a wide variety of prokaryotes and eukaryotes in
different forms [5]. It is widely distributed in human tissues
and shows highest activity in lymphoid tissues and it is
necessary for the proliferation, maturation and function of
lymphocytes, speciﬁcally for T lymphocytes [5,6]. The ADA is
widely distributed in animal and human tissues [4]. It is
present in the cytoplasmic fraction and a certain amount isen access article under the CC BY-NC-ND
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critical in controlling the effects of these metabolites on
immunological, neurological and vascular systems [8]. The
AMP-aminohydrolase (AMPDA) is a key enzyme of nucleo-
tide breakdown involved in regulation of adenine nucleotide
pool in the liver and energetic metabolism in mammalian cells
[9]. Also, it plays a crucial role in the synthesis of guanine
nucleotides and in the provision of anaplerotic substrates for
the Krebs cycle [9]. The highest ADA activity has been
reported in lymphoid and fatty tissues, liver, skeletalmuscle,
and heart [10].
Small ubiquitin-like modiﬁer (SUMO) proteins are a family
of main proteins belongs to the ubiquitin and ubiquitin-like
protein family [11]. SUMOylation is a part of important
regulatory mechanisms that adjust proteins in the nucleus and
control multiple cellular processes such as nucleo-cytoplasmic
signal transduction, apoptosis, stress responses, protein stabil-
ity, subcellular localization of proteins, protein–protein in-
teractions, protein-DNA interactions, and transcriptional activity
of transcription factors and progression through the cell cycle
[12–14]. Very few studies on patients with renal disease have been
reported, which are controversial with respect to serum ADA
and AMPDA activity [15,16]. On the other hand no one has
reported on serum ADA and AMPDA activities in patients
with renal stones. Thus, in the current study, we aimed to
observe the correlation of serum ADA and AMPDA activities
to E3 SUMO-protein ligase NSE2 (NSMCE2) patients with
renal stones and assess the possibility of a new biomarker for the
evaluation of kidney damage. Also the study aimed to give a
comprehensive study of adenosine aminohydrolase including
separation, characterization and puriﬁcation from sera of patients
with renal stone and control using several biochemical
techniques.
2. Materials and methods
The present work had been done under the support from the
International Islamic University Malaysia (IIUM), the Research
Management Center Grant Scheme Project No. IIUM/504/5/29/
1. The IIUM Research Ethics Committee (IREC) operates in
according to Declaration of Helsinki International Conference of
Harmonization Goof Clinical Practice Guidelines (ICH-GCP),
Malaysia Good Clinical Practice Guidelines and Council for
International Organization of Medical Sciences (CIOMS) In-
ternational Ethical Guidelines, No. IIUM/305/14/11/2/IREC 300
on October 2014. A total of sixty patients with renal stone and
ﬁfty healthy as control were included in this study. These pa-
tients were hospitalized at government health clinics in Kuan-
tan–Pahang. Five milliliter of blood sample was collected and
the blood was allowed to clot for at least 10–15 min at room
temperature, centrifuged for 10 min at 3000 r/min. The levels of
serum urea, creatinine, uric acid and albumin were measured by
spectrophotometric methods supplied by Randox kits. The
NSMCE2 assay employs the quantitative sandwich enzyme
immunoassay.
2.1. Determination of ADA and AMPDA activities and
total protein
The ADA activity was determined according to Giusti method
[17]. The activity was measured using spectrophotometer. ADAunit was deﬁned as the amount of enzyme which forms one
micromole of ammonia in one minute. Determination of
AMPDA activity was carried out according to Gromashevskaia
method [18]. Serum total protein was estimated by Lowery et al.
method [19].
2.2. Partial puriﬁcation of ADA
2.2.1. Ammonium sulfate precipitation
Protein was precipitated using solid ammonium sulfate [20].
The supernatant was separated by cooling centrifugation at
(10,000 r/min) for 30 min. Protein concentration and ADA
activity was measured.
2.2.2. Dialysis
The dialysis sac containing the suspension in Step 2.2.1. was
dialyzed overnight at 4 C using sodium bicarbonate. The ﬁnal
volume measured and the protein concentration was assessed,
and the ADA activity was determined [17].
2.2.3. Gel ﬁltration chromatography
Gel ﬁltration chromatography was used for partial puriﬁca-
tion of ADA enzyme, and two milliliter of the sample was used
to a column (2 × 87 cm) comprising sephadex G-100 to 85 cm
height. Elution was carried out at ﬂow rate of 70 mL/h, using
phosphate buffer (pH = 6.5) as eluent, the fractions were
collected; ADA activity and the protein concentration were
measured. All steps were done at 4 C.
2.3. Kinetic parameters (Km and Vmax)
2.3.1. Effect of substrate concentration
ADA enzymatic reaction was carried out in optimum reaction
condition using altered concentrations of adenosine as a sub-
strate (0.002, 0.005, 0.010, 0.015, 0.020, 0.025, 0.030, 0.040
and 0.050 mmol/L). The correlation between each substrate
concentration and the enzyme activity was plotted in order to
determine the optimum substrate concentration for each enzyme
activity. Then the values of Km and Vmax for ADA to substrate
were determined by using the Lineweaver-Burk plot (the rela-
tionship between 1/V versus 1/Substrate).
2.3.2. Effect of the pH
The enzymatic reaction was carried out via buffers with
different pH (4.5, 5.5, 6.0, 6.5, 7.5, 8.5, 9.5 and 10.5) for Vmax.
The optimum pH was estimated by scheming the relationship
between the enzyme activities versus the pH values.
2.3.3. Effect of the temperature
ADA enzymatic reaction was carried out in optimum reaction
condition using different temperatures (20, 25, 30, 35, 37, 40,
45, 50, 55 C). The optimum temperature was evaluated by
plotting the correlation between the enzyme activities versus the
temperature values.
2.3.4. Thermodynamic parameters
The thermodynamic parameters of the transition state [Ea, the
enthalpy of transition state (DH*), the transition state of free
energy change (DG*), the change in entropy of the transition
state (DS*)] were estimated from Arrhenius plot of ln K+1
Table 1
The age, serum urea, creatinine, protein, albumin, uric acid and NSMCE2 in patients group and control group (mean ± SD).
Group Age (year) Blood urea
(mg/dL)
Serum creatinine
(mg/dL)
Serum protein
(g/dL)
Serum albumin
(g/dL)
Serum uric
acid (mg/dL)
NSMCE2
(pg/mL)
Patients group (n = 60) 52.42 ± 10.19 40.25 ± 7.57 1.16 ± 0.42 7.65 ± 0.43 4.39 ± 0.58 6.90 ± 0.94* 80.41 ± 8.45**
Control group (n = 50) 50.27 ± 8.21 37.89 ± 8.36 1.10 ± 0.24 7.68 ± 0.32 4.61 ± 0.57 5.32 ± 0.53 70.04 ± 107.81
*P < 0.05, **P < 0.01 compared to control group.
Table 2
The serum ADA, AMPDA and speciﬁc activity in patients and control groups (mean ± SD).
Group ADA AMPDA
Activities (IU/L) Speciﬁc activity (IU/mg) Activities (IU/L) Speciﬁc activity (IU/mg)
Patients group (n = 60) 11.63 ± 4.00* 0.15 ± 0.05* 9.51 ± 3.45* 0.12 ± 0.06*
Control group (n = 50) 17.56 ± 7.48 0.24 ± 0.09 14.22 ± 5.37 0.19 ± 0.08
*P < 0.05 compared to control group.
Table 3
Correlation between NSMCE2 with several biochemical parameters in
patients and control groups.
Characteristics NSMCE2 in
patients (pg/mL)
NSMCE2 in
control (pg/mL)
Pearson
correlation
Sig. Pearson
correlation
Sig.
ADA (IU/L) −0.76 0.01 0.09 N.S
AMPDA (IU/L) −0.80 0.01 0.11 N.S
Uric acid (mmol/L) 0.62 0.01 0.10 N.S
Sig.: Signiﬁcance (2-tailed). N.S: Not signiﬁcant.
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according to the Arrhenius equation:
ln K+1 = −Ea/RT + A
The activation energy of the binding reaction was calculated
from the slope of the straight line.where, A represents for Arrhe-
nius constant, Ea represents for the activation energy, R represents
for the gas constant and T represent for absolute temperature.
2.3.4.1. Determination of the activation energy and
temperature coefﬁcient
The relation between the activation energy and temperature
coefﬁcient were determined by using the equation:
Ea = 2.3 RT2T1 log Q10/10
where, Q10 is the temperature coefﬁcient, R is the gas constant,
T is the temperature, Ea is the activation energy.
2.3.4.2. Determination of the DH*, DS* and DG*
The enthalpy of transition state (DН*) was determined from
the following equation:
DН* = E − RT
The transition state of free energy change (DG*) was calcu-
lated from the following equation:
DG* = −RT ln K+1 + RT ln KT/h
where, K is Boltzmann constant (1.38 × 10–23 J/K), h is Plank
constant (6.62 × 10–34 J sec).
The change in entropy of the transition state (DS*) was
calculated from the following formula:
DS* = (DH* − DG*)/T
2.4. Statistical analysis
All statistical analyses in studies were performed using SPSS
version 20.0 for Windows. Descriptive analysis was used toshow the mean ± SD of variables. The signiﬁcance of difference
between mean values was assessed by student's t-test. The
probability P < 0.05 means signiﬁcant, P > 0.05 means non-
signiﬁcant.
3. Results
A total of 60 of patients with renal stone and ﬁfty control
were included in the current study. The present study showed
that blood urea, serum creatinine, serum albumin and total serum
protein have been non signiﬁcantly different (P > 0.05)
compared to control group (Table 1). It also indicated a signif-
icant increases in serum NSMCE2 and uric acid (P < 0.01) and
(P < 0.05) respectively for diagnosed patients compared to
control group (Table 1).
The current study showed that mean ADA and AMPDA
activities and speciﬁc activity have been signiﬁcantly decreased
(P < 0.05) in patients with renal calculi compared to control
group (Table 2).
There were a signiﬁcant different correlations between
NSMCE2 with ADA, AMPDA and uric acid in patients with
renal stones compared to control group (Table 3).
Tables 4 and 5 showed the puriﬁcation by ammonium sulfate,
making it most appropriate for the preparation of a protein that is
vulnerable to proteolytic degradation such as ADA in patients
and control groups. The speciﬁc activity was a slight increased
after dialysis. This may possibly be due to the exclusion of the
small molecules and increase the puriﬁcation of enzyme.
Figures 1 and 2 show that there is mainly one peak by gel
ﬁltration separations for patients and control group respectively.
Table 4
Partial puriﬁcation steps of ADA from patients with renal stones.
Puriﬁcation stage Volume
(mL)
Activity
(IU/L)
Total
activity (IU)
Total
protein (g/L)
SA (IU/min/
mg protein)
Yield
(%)
Folds of
puriﬁcation
Crude 10.0 13.20 132.00 75.98 0.17 100.00 1.00
Ammonium sulfate
supernatant
4.5 24.35 109.58 49.78 0.49 83.02 2.88
Dialysis 2.5 36.55 91.38 26.23 1.39 69.23 8.18
Sephadex G-100 21.0 3.75 78.75 1.98 1.89 59.65 11.12
SA: Speciﬁc activity.
Table 5
Partial puriﬁcation steps of ADA from control group.
Puriﬁcation stage Volume
(mL)
Activity
(IU/L)
Total
activity (IU)
Total
protein (g/L)
SA (IU/min/
mg protein)
Yield
(%)
Folds of
puriﬁcation
Crude 10.0 18.10 181.00 77.65 0.23 100.00 1.00
Ammonium
sulfate supernatant
5.4 28.44 153.58 51.43 0.55 84.85 2.39
Dialysis 3.2 39.22 125.50 27.00 1.45 69.34 6.30
Sephadex G-100 21.0 5.00 105.00 2.16 2.31 58.00 10.04
SA: Speciﬁc activity.
Figure 1. Elution proﬁle of ADA from sera of patients with renal stones
using Sephadex G-100, ﬂow rate (70 mL/h) and column (2 × 87 cm).
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than the activity in initial extract (Table 4) for patients group and
speciﬁc activity of the enzyme was increased in 10.04 folds for
control group.Figure 2. Elution proﬁle of ADA from sera of control group using
Sephadex G-100, ﬂow rate (70 mL/h) and column (2 × 87 cm).The total activity of ADA (78.75 IU/L) with 59.65% recov-
ery for patients group, while the total activity of ADA
(105.00 IU/L) with 58.00% recovery for control group are
shown in Tables 4 and 5, respectively.Figure 3. Effect of substrate concentration on ADA activity. A: Control
group; B: Patients group.
Figure 4. Determination of Km and Vmax for ADA of in partial puriﬁed
ADA using Lineweaver–Burk plot. A: Control group; B: Patients group.
Figure 5. Effect of temperatures and pH on ADA activity. A: Effect of pH;
B: Effect of temperatures.
Figure 6. Arrhenius plot between inverse temperature and log Vmax. A:
Control group; B: Patients group.
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different concentrations (0.002, 0.005, 0.010, 0.015, 0.020,
0.025, 0.030, 0.040, 0.050 mmol/L) of adenosine as a substrate.
It was found that the maximum activity of the enzyme was
obtained by using (0.020 mmol/L) of adenosine in both patients
and control groups (Figure 3).
Figure 4 showed Lineweaver–Burk plot by plotting the
reciprocal of the initial velocity versus the reciprocal of the
substrate concentration. A linear relationship was obtained with
a Vmax (15.70 IU/L) and Km value of (0.047 mmol/L) in
control group and a Vmax (12.77 IU/L) and Km value of
(0.066 mmol/L) for patient with renal stones. To our knowledge
no previous study has puriﬁed and determined kinetic study of
ADA in patients with renal stones.
The pH (4.5, 5.5, 6.0, 6.5, 7.5, 8.5, 9.5, 10.5) effect on ADA
activity has been studied in patients and control group
(Figure 5A). The activity of partial puriﬁed ADA increasedTable 6
Thermodynamic parameters at transition state in patients with renal
stones and normal subjects.
Case Ea*
(KJ/mol)
DH*
(KJ/mol)
DG*
(KJ/mol)
DS*
(J/mol.K)
Patients group 20.31 17.73 96.33 −253.55
Control group 24.92 22.34 87.46 −210.06
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maximum at 37 C for patients and control groups (Figure 5B).
The role of enzyme catalyzed reactions, similar to chemical re-
action, increased with temperature.
The thermodynamic parameters of the transition state were
estimated from Arrhenius plot of ln K+1 values against (1/T)
values (Figure 6).
A linear relationship was obtained with the activation energy
of 4854.64 cal/mol and the temperature coefﬁcient of 1.84 in
patients group and the activation energy of 5955.44 cal/mol and
the temperature coefﬁcient of 1.98 in control group.
Table 6 shows the values of DH*, DS* and DG* in transition
state for enzyme–substrate ([ES]) complex reaction.
4. Discussion
The present result come to an agreement with other studies
which hypothesized that renal stones and urinary calculus have
been associated with increased levels of uric acid in the blood
[21,22]. Several papers have described elevated uric acid is an
independent risk factor for kidney disease in the general
population [23,24]. Another clinical study found that lowering
uric acid in patients with renal disease and asymptomatic
hyperuricemia resulted in less progression of their renal
disease [25]. Uric acid is the main product of catabolism of
the purine nucleosides. Usually two thirds to three fourths of
it is excreted via the kidneys, and residual by the intestines.
Renal control of uric acid is complex [26]. Glomerular
ﬁltration of practically all uric acid occurs in capillary
plasma incoming the glomerulus followed by reabsorption of
about 98–100% of uric acid in proximal convoluted tubular.
The following secretion of half of reabsorbed uric acid
takes place in distal portion of proximal tubule and post-
secretory reabsorption of 40% of secreted uric acid in distal
tubule [27].
Several studies dedicated on ROS-mediated SUMOylation,
which is one of the posttranslational differences, which may be
due to possible implications on vascular inﬂammation [28,29].
SUMOylation regulates fundamental cellular processes such as
apoptosis, response to cellular stress and cellular proliferation
[30]. The SUMO modiﬁcation of proteins has been submitted
to adjust various physiological progresses, such as stress
responses, transcriptional regulation, and protein localization.
Recent studies indicate a role for SUMOylation in the
regulation of inﬂammation [28]. Inﬂammation is initiated in
response to kidney tissue damage. Inﬂammatory responses
must be regulated properly, and unrestricted inﬂammation can
lead to inﬂammatory disorders in patients with kidney stones.
Furthermore the rise in NSMCE2 may possibly be due to
ampliﬁed free radicals effects which subsequently leads to an
increase in damage in DNA and because of the dynamic role
of this enzyme in the treatment of damage made in the DNA.
Certainly adenosine and its metabolites weaken lymphocyte
function and proliferation in a dose dependent manner, lower
ADA intracellular adenosine concentration and also inactivates
T cells [31]. The AMPDA is the rate-limiting step for entry
into the purine nucleotide cycle and catalyzes the conversion of
adenosine monophosphate to inosine monophosphate [31]. The
insufﬁciency of ADA activity leads to severe
immunodeﬁciency disease in which T-lymphocytes and B-
lymphocytes do not develop appropriately, which means that
ADA is a non-speciﬁc indicator of the activation of the T andB cells, which has a signiﬁcant role in the etiology of numerous
disease [32].
The results showed that maximum enzyme activity was at pH
6.5 in partial puriﬁed ADA in patients and control groups. The
velocity of enzyme-catalyzed reactions depends on pH. En-
zymes have optimum pH and frequently give bell-shaped curves
of velocity against pH, even though other shapes have been
observed [20]. The decrease in ADA activity at low pH may be
due to consequence of pH environment of reaction in ionic
groups in active site or changing in ionic state for substrate or
complex enzyme-substrate at the concentration of substrate
above than Km, if the substrate concentration is small, it will
depend on enzyme [33]. The result of the present study showed
that, above and below optimum temperature, serum ADA
enzyme is more heat stable in patients than in normal. This
might be due to the alterations in the ratio of isoenzymes in
the serum of patient for the reason that isoenzymes have not
the same stability to temperature. The tertiary structure of an
enzyme is kept principally by amounts of non-covalent links.
When molecule absorbs much energy the tertiary structure will
broke, and enzyme will be denatured, which loses enzymes
activity [34].
The DH* value of ADA in patients and control groups was
positive and this point to enzyme reaction is endothermic and
need energy for the formation of [ES*] complex. The DG* was a
positive value, this indicates that the reaction of ES formation is
anon spontaneous, nevertheless needs energy therefore called
endergonic reaction. The DG* value of this reaction is inde-
pendent on molecular pathway of mechanism of transformation
[35]. The DS* value of ADA was negative, so indicate that the
complex [ES*] more arranged than enzyme, wherever the
negative value of DS* reverse through increasing the structure
arrangement [35].
In conclusion, the reduction of ADA and AMPDA activities
could cause a state of immune suppression, also the increase in
NSMCE2 may play a role in development of DNA damage and
inﬂammation disorders in the patients with kidney stones. The
increase in NSMCE2 and the decrease in ADA and AMPDA
activities could be as a good indicator for complication of renal
calculi.
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